Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rena Buckstein

Showing results (31-40 of 133) with videos related to

Pageof 14
Sort By:
Annals of Hematology|October 2, 2021
Previously unreported WRAP53 gene variants in a patient with dyskeratosis congenitaEugene Brailovski, Hubert Tsui, Yi-Bin Chen, et al.
Experimental Hematology|August 23, 2017
Tet2 restrains inflammatory gene expression in macrophagesAlyssa H Cull, Brooke Snetsinger, Rena Buckstein, et al.
Leukemia Research|June 28, 2011
Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosisJ Rauw, R A Wells, A Chesney, et al.
Journal of the National Cancer Institute|October 22, 2016
The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based StudyLee Mozessohn, Craig Earle, David Spaner, et al.
Psycho-Oncology|October 24, 2008
The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysisMatthew C Cheung, Kevin R Imrie, Jessica Friedlich, et al.
Leukemia & Lymphoma|February 11, 2020
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'Lee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
JCO Oncology Practice|September 21, 2020
Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid LeukemiaLee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Journal of the National Cancer Institute|April 20, 2017
ResponseLee Mozessohn, Craig C Earle, David Spaner, et al.
Leukemia Research|March 14, 2009
Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrowsRena Buckstein, Karen Jang, Jessica Friedlich, et al.
Leukemia & Lymphoma|June 3, 2014
Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromesHany R Guirguis, Lauren F Charbonneau, Ivan Tyono, et al.
Pageof 14

Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
Annals of Hematology|October 2, 2021
Previously unreported WRAP53 gene variants in a patient with dyskeratosis congenitaEugene Brailovski, Hubert Tsui, Yi-Bin Chen, et al.
Experimental Hematology|August 23, 2017
Tet2 restrains inflammatory gene expression in macrophagesAlyssa H Cull, Brooke Snetsinger, Rena Buckstein, et al.
Leukemia Research|June 28, 2011
Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosisJ Rauw, R A Wells, A Chesney, et al.
Journal of the National Cancer Institute|October 22, 2016
The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based StudyLee Mozessohn, Craig Earle, David Spaner, et al.
Psycho-Oncology|October 24, 2008
The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysisMatthew C Cheung, Kevin R Imrie, Jessica Friedlich, et al.
Leukemia & Lymphoma|February 11, 2020
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'Lee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
JCO Oncology Practice|September 21, 2020
Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid LeukemiaLee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Journal of the National Cancer Institute|April 20, 2017
ResponseLee Mozessohn, Craig C Earle, David Spaner, et al.
Leukemia Research|March 14, 2009
Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrowsRena Buckstein, Karen Jang, Jessica Friedlich, et al.
Leukemia & Lymphoma|June 3, 2014
Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromesHany R Guirguis, Lauren F Charbonneau, Ivan Tyono, et al.
Pageof 14